Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

New early breast cancer treatment significantly reduces the risk of cancer returning

Marking the first major treatment advance since tamoxifen's introduction over 25 years ago, Canada's leading oncologists and breast cancer patient support and advocacy groups gathered to applaud a new era in treatment for early breast cancer.

15 Jul 2004

Strategic analysis of the breast cancer therapeutics pipeline

Strategic partnerships between the pharmaceuticals industry and the biotechnology sector are making breast cancer therapeutics one of the most dynamic segments in the overall oncology market.

15 Jul 2004

Stress may increase risk for the most common type of uterine cancer

Research in monkeys suggests the possibility that stress may increase risk for the most common type of uterine cancer, according to a report from Wake Forest University Baptist Medical Center.

10 Jul 2004

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people or 10% of the 500,000 people in the U.S with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery for coverage of life saving drugs.

26 Jun 2004

Cognitive decline can occur before chemotherapy treatment

In a series of studies in breast cancer patients, researchers at The University of Texas M. D. Anderson Cancer Center have confirmed the presence of “chemobrain” after chemotherapy treatment – but they also discovered that a significant portion of patients have cognitive declines even before chemotherapy.

21 Jun 2004

Cancer drug gefitinib (Iressa) may be able to restore tamoxifen's anticancer activity

A new study has found a possible mechanism for tamoxifen resistance in breast cancer and provides evidence that another cancer drug--gefitinib (Iressa)--may be able to restore tamoxifen's anticancer activity.

15 Jun 2004

Better understanding of Tamoxifen and how breast cancer patients develop resistance

A new study by researchers at Georgetown’s Lombardi Comprehensive Cancer Center may have implications for the thousands of breast cancer patients who develop resistance to antiestrogen drugs such as Tamoxifen®. The work is published in the June 1 issue of Cancer Research.

11 Jun 2004

New treatment significantly improves long-term outlook for breast cancer survivors

An updated analysis from an international clinical trial of the drug letrozole was presented on June 8, 2004 at the American Society of Clinical Oncology annual meeting in New Orleans.

11 Jun 2004

Gene mutation found in some women may decrease effectiveness of tamoxifen breast cancer drug

Researchers from the Johns Hopkins Kimmel Cancer Center, Indiana University and the University of Michigan have found that some women have a gene mutation that may decrease the effectiveness of tamoxifen, a commonly used breast cancer drug.

7 Jun 2004

Serum estrogen receptor modulator's (SERM's) may help reduce postmenopausal breast cancer risk

Newest research findings were presented on the possible benefits they may provide for postmenopausal breast cancer risk reduction. SERMs are a class of drugs that can block the cell's ability to use estrogen to stimulate the development of breast cancer.

7 Jun 2004

There are still benefits from hormone therapy after menopause

Despite the highly publicized closing of the Women’s Health Initiative study, the scientific community should not rule out that women may benefit from hormone therapy after menopause, say researchers at UC Davis, Duke and Harvard Universities.

31 May 2004

Women who regularly take aspirin at lower risk of breast cancer

Women who regularly take aspirin seem to be at lower risk of the most common type of breast cancer than those who do not take aspirin, report researchers from Columbia University's Mailman School of Public Health and College of Physicians & Surgeons, Weill Cornell Medical College , and New York-Presbyterian Hospital.

31 May 2004

Largest study ever finds male breast cancer on the rise

The rate of male breast cancer is on the rise and the disease in men is usually detected when the tumors are bigger, have spread and may be more aggressive, compared to diagnosis of the disease in women, concludes the largest study ever conducted of male breast cancer.

24 May 2004

New studies put spotlight on replicative capacity of beta cells

Researchers at Harvard University and the Howard Hughes Medical Institute (HHMI) have discovered that insulin-producing beta cells in the pancreas that are attacked in type 1 diabetes are replenished through duplication of existing cells rather than through differentiation of adult stem cells.

5 May 2004

Significant drop in breast cancer death rates and rise in screening

Breast cancer related deaths in Scotland have fallen by more 25 percent since 1990, figures out today show.

28 Apr 2004

North America's largest-ever breast cancer enrolls 19,000th participant

Leaders of North America's largest-ever breast cancer prevention trial, the Study of Tamoxifen and Raloxifene (STAR), are striving to reach a major milestone this summer: the enrollment of the study's 19,000th — and final — participant.

14 Apr 2004

Researchers tap modified plant viruses to ward off cervical cancer-causing infections

New vaccinations to prevent infections that lead to cervical cancer and targeted therapeutics aimed at breast cancer were examples of research highlights presented by scientists today at the 95th Annual Meeting of the American Association for Cancer Research. Scientists described advances that feed into the drug development 'pipeline,' and show strong promise for controlling existing tumors or addressing the pathogen that causes tumors.

29 Mar 2004

Pfizer breast cancer drug looks to be best in field

A breast cancer drug made by Pfizer Inc. increased survival rates by 63 percent compared with the standard therapy tamoxifen, researchers said on Wednesday. The clinical trial strengthens the case for administering the newer drug, exemestane, as a first option. A study published last week showed that women recovering from breast cancer lowered their chance of developing another tumor by 32 percent if they switched to exemestane after two or three years of tamoxifen treatment.

22 Mar 2004